Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833866 | 1.00 | CYP19A1 (0.42) | CYP19A1IMPDH2CSNK1DCSNK1ECLK1 | |
| SCHEMBL1127906 | 0.92 | PRKCZ (0.46) | CYP19A1IMPDH2CSNK1DCSNK1ECLK1 | |
| SCHEMBL1793381 | 0.80 | CYP2A6 (0.38) | — | |
| SCHEMBL15941610 | 0.77 | ALDH1A1 (0.38) | — | |
| SCHEMBL8878299 | 0.73 | CSNK1D (0.38) | CSNK1DCSNK1ECLK1DYRK1A | |
| SCHEMBL30969150 | 0.72 | CYP2A6 (0.59) | CYP19A1IMPDH2PRKCZPRMT3ROCK2 | |
| SCHEMBL2616771 | 0.72 | CYP2A6 (0.59) | CYP19A1IMPDH2PRKCZPRMT3ROCK2 | |
| SCHEMBL152013 | 0.72 | CYP19A1 (0.45) | CYP19A1IMPDH2CSNK1DCSNK1ECLK1 | |
| SCHEMBL11143684 | 0.72 | MAPT (0.56) | CYP19A1IMPDH2CYP3A4PRMT3ALOX15 | |
| SCHEMBL5952419 | 0.72 | CYP2A6 (0.48) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240376145-A9 | STEROIDAL COMPOUND DERIVATIVES AS THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240083936-A1 | STEROIDAL COMPOUND DERIVATIVES AS THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2022133265-A1 | STEROIDAL COMPOUND DERIVATIVES AS THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORTED (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083936-A1 | STEROIDAL COMPOUND DERIVATIVES AS THERAPEUTIC AGENTS | PGF, HPGDS, NR5A1 | CYP19A1 16/4885IMPDH2 2997/4885CSNK1D 1876/4885 |
| US-12552830-B2 | Steroidal compound derivatives as therapeutic agents | PGF, NR3C2, NR5A1 | CYP19A1 96/4885IMPDH2 3824/4885CSNK1D 215/4885 |
| US-20240376145-A9 | STEROIDAL COMPOUND DERIVATIVES AS THERAPEUTIC AGENTS | PGF, HPGDS, NR5A1 | CYP19A1 16/4885IMPDH2 2997/4885CSNK1D 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.